Repligen price target lowered to $180 from $240 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Repligen (RGEN) to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the coming year. It lowered the price target saying Repligen’s “explosive growth” of the COVID-19 years is no longer evident, but notes that the company’s risk profile and overall positioning remain attractive.